E 20 More Psychedelic Stocks

On average the above 6 stocks went UP 50.0% last week.

Segment Three

The following company is doing research into the use of mescaline, a psychoactive compound similar to psilocybin that can be extracted from the Peyote cactus.

  1. Nutritional High International Inc. (SPLIF) +/-0%
    • In June, while the company is primarily focused on developing and manufacturing branded cannabis products for the U.S. market, it purchased Kruzo LLC.
      • Kruzo is focused on developing products and conducting research on mescaline, a psychoactive compound similar to psilocybin that can be extracted from the Peyote cactus and will provide an important source of future product innovation and diversification.
      • Kruzo has a working relationship with Rangsit University in Thailand to investigate the utility and efficacy of combining mescaline and other Peyote alkaloids with traditional Asian herbal products as well as CBD and other cannabinoids.
    • In August the company acquired Psychedelic Science Corp. (PSC), a company focused on developing psychedelic cacti-based wellness and pharmaceutical products to address weight loss, insomnia, anxiety, and pain.
      • The PSC team is also assessing various non-psychoactive, cactus-based wellness products that are legal for sale and distribution in the U.S. and Canada.
    • For more information on the company visit its website here.

Segment Four

Below are the remaining three psychedelic drug stocks that make up the sector (they either trade in excess of $1/share and/or have a market cap in excess of $75M) with a description of their business and their performances last week:

  1. Compass (CMPS) +40.3% (Mkt. Cap: $1.3B)
    • COMPASS has a psilocybin-based therapy for treatment-resistant depression in Phase 2 of clinical trials. For more information on the company visit its website here.
  2. MindMed (MMEDF) +36.8%  (Mkt. Cap: $273.5M)
    • MindMed has three drug initiatives that use psychedelic mushrooms already in Phase 2 with several other initiatives in Phase 1 trials. For more information on the company visit its website here.
  3. Field Trip (FTRPF) +3.0% (Mkt. Cap: $84.1M)
    • Field Trip is conducting advanced research on plant-based psychedelics such as ketamine as a treatment option for PTSD. For more information on the company visit its website here.

On average the above 3 stocks went UP 36.7% last week.

1 2 3
View single page >> |

Disclosure:This article discusses one or more penny stocks and/or microcaps. Such stocks are easily manipulated; do your own careful due diligence.

Visit   more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.